Professor Gary Wittert, Senior Endocrinologist and Director of the FFCMH has recently co-authored with Australian experts two position statements on testosterone supplementation on behalf of the Endocrine Society of Australia, and published these in the Medical Journal of Australia.
Yeap BB, Grossmann M, McLachlan RI, Handelsman DJ, Wittert GA, Conway AJ, Stuckey BG, Lording DW, Allan CA, Zajac JD, Burger HG.Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. Med J Aust. 2016;15;205:173-8.
Yeap BB, Grossmann M, McLachlan RI, Handelsman DJ, Wittert GA, Conway AJ, Stuckey BG, Lording DW, Allan CA, Zajac JD, Burger HG.Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations. Med J Aust. 2016;205:228-31.
As stated in the first of two MJA articles, “The Endocrine Society of Australia last formulated guidelines for testosterone prescription in 2000, aiming to restrict inappropriate usage. Since then, prescriptions of testosterone have risen dramatically in Australia and elsewhere without any new proven indications, consistent with its use extending beyond the treatment of men with pathological hypogonadism due to pituitary or testicular disease.”
While testosterone supplementation is warranted in men with pathological hypogonadism, there are limited data to justify testosterone treatment in older men with chronic disease who have low circulating testosterone in absence of any pathology. Evidence of whether, indeed, testosterone has a benefit in men for preventing progression of chronic disease such as type 2 diabetes is being gathered by a large scale national clinical trial led by Professor Wittert – the T4DM study – which closed recruitment in Dec 2016.
The publication of the position statements was also accompanied by a re-airing of a 2014 Catalyst show on testosterone for health in which Professor Wittert featured.